Heath Lukatch Net Worth

The estimated Net Worth of Heath Lukatch is at least $433 Thousand dollars as of 31 January 2024. Heath Lukatch owns over 5,000 units of Inogen Inc stock worth over $122,825 and over the last 9 years he sold INGN stock worth over $0. In addition, he makes $310,022 as Independent Chairman of the Board at Inogen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Heath Lukatch INGN stock SEC Form 4 insiders trading

Heath has made over 18 trades of the Inogen Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of INGN stock worth $80,000 on 31 January 2024.

The largest trade he's ever made was exercising 13,000 units of Inogen Inc stock on 2 January 2024 worth over $208,000. On average, Heath trades about 1,291 units every 57 days since 2015. As of 31 January 2024 he still owns at least 10,625 units of Inogen Inc stock.

You can see the complete history of Heath Lukatch stock trades at the bottom of the page.

Heath Lukatch biography

Dr. Heath Lukatch, Ph.D., is an Independent Chairman of the Board of Company. Dr. Lukatch is Founder and Managing Partner of Red Tree Venture Capital. Previously Dr. Lukatch was a Partner and Managing Director at TPG Biotech from 2015 until March 2020. Prior to joining TPG Biotech, Dr. Lukatch was a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo Holdings A/S. Dr. Lukatch joined Novo Ventures (US) Inc. in 2006. From 2001 to 2006, Dr. Lukatch was a Managing Director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners, a private equity firm and spin off of Piper Jaffray Ventures. Prior to joining Piper Jaffray Ventures, Dr. Lukatch worked as a strategy consultant with McKinsey & Company, a consulting firm, from 1997 to 2000. Dr. Lukatch also served as co-founder and Chief Executive Officer of AutoMate Scientific, a biotechnology instrumentation company from 1991 to 1997, and held scientific positions with Chiron Corporation, a biotechnology company, from 1990 to 1991, Roche Bioscience, a healthcare company, from 1996 to 1997, and Cetus Corporation, a biotechnology company, in 1987. He currently serves on the Boards of Directors of Adynxx, Ceribell, Engage Therapeutics, Flexion Therapeutics, Inc. (FLXN), Halo Neuroscience, Satsuma Pharma, SutroVax, Viacyte and ViewPoint Therapeutics. Dr. Lukatch received his Ph.D. in Neuroscience from Stanford University where he was a DOD USAF Fellow, and his Bachelor of Arts in Biochemistry from the University of California at Berkeley. The Board believes that he is qualified to serve as a director of Inogen because of his extensive industry experience and experience as a venture capital investor and a board member for several venture-backed healthcare companies.

What is the salary of Heath Lukatch?

As the Independent Chairman of the Board of Inogen Inc, the total compensation of Heath Lukatch at Inogen Inc is $310,022. There are 8 executives at Inogen Inc getting paid more, with Scott Wilkinson having the highest compensation of $2,520,530.

How old is Heath Lukatch?

Heath Lukatch is 53, he's been the Independent Chairman of the Board of Inogen Inc since 2008. There are 9 older and 7 younger executives at Inogen Inc. The oldest executive at Inogen Inc is Benjamin Anderson-Ray, 65, who is the Independent Director.

What's Heath Lukatch's mailing address?

Heath's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070.

Insiders trading at Inogen Inc

Over the last 11 years, insiders at Inogen Inc have traded over $242,179,025 worth of Inogen Inc stock and bought 9,125 units worth $253,950 . The most active insiders traders include Holdings A/S Novo, Timothy Petersen, and Raymond Huggenberger. On average, Inogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $321,391. The most recent stock trade was executed by Jason Somer on 1 June 2024, trading 577 units of INGN stock currently worth $6,670.

What does Inogen Inc do?

inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take

Complete history of Heath Lukatch stock trades at Flexion Therapeutics Inc, Inogen Inc, Vaxcyte, and Satsuma Pharmaceuticals

Inogen Inc executives and stock owners

Inogen Inc executives and other stock owners filed with the SEC include:

• Scott Wilkinson,
  President, Chief Executive Officer, Director
• Alison Bauerlein,
  Executive Vice President - Finance and Chief Financial Officer, Corporate Secretary and Corporate Treasurer
• Bart Sanford,
  Executive Vice President, Operations
• Byron Myers,
  Executive Vice President of Marketing
• Brenton Taylor,
  Executive Vice President - Engineering
• Dr. Stanislav Glezer M.D., MBA,
  Exec. VP & CTO
• Alison Perry Bauerlein,
  Co-Founder
• Bart Sanford,
  Exec. VP of Operations
• Heath Lukatch,
  Independent Chairman of the Board
• Heather Rider,
  Independent Director
• R. Scott Greer,
  Independent Director
• Loren McFarland,
  Independent Director
• Benjamin Anderson-Ray,
  Independent Director
• Raymond Huggenberger,
  Independent Director
• Matt Bacso,
  IR Contact Officer
• Scott Beardsley,
  Independent Director
• Arron Retterer,
  Executive Vice President of Sales
• Jennifer Yi Boyer,
  Exec. VP & Chief HR Officer
• Agnes Lee,
  Sr. VP of Investor Relations & Strategic Planning
• Kristin A. Caltrider,
  Exec. VP, CFO & Treasurer
• Matthew Pigeon,
  Investor Relations Officer
• George J. Parr,
  Exec. VP & Chief Commercial Officer
• Jason Somer,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Matthew James Bacso C.F.A.,
  Investor Relations & Corp. Devel. Mang.
• Michael K. Sergesketter,
  Interim Chief Financial Officer
• Nabil Shabshab,
  CEO, Pres & Director
• Kevin M King,
  
• Matt Scribner,
  See Remarks
• George J Parr,
  Chief Commercial Officer
• William J Phd Link,
  Director
• Ventures Ii Llc Versant Ven...,
  
• Kristin A. Caltrider,
  EVP, CFO and Treasurer
• Ventures Ii Llc Versant Ven...,
  
• Ventures Ii Llclink William...,
  
• Ventures Ii Lp Arboretum Ve...,
  
• Stephen E. Cooper,
  Director
• Ventures Ii Llc Versant Ven...,
  
• Ventures Ii Llc Versant Ven...,
  
• Ventures Ii Llc Versant Ven...,
  
• Holdings A/S Novo,
  10% owner
• Charles E Larsen,
  Director
• Timothy Petersen,
  Director
• Ventures Ii Llc Versant Ven...,
  
• Kevin Raymond Merrill Smith,
  CEO and President
• Kristen Miranda,
  Director
• Nabil Shabshab,
  CEO and President
• Stanislav Glezer,
  EVP, R&D & Chief Med. Officer
• Jason Somer,
  EVP, Gen. Counsel & Secretary
• Michael J. Bourque,
  EVP, CFO & Treasurer
• Elizabeth Mora,
  
• Thomas A. West,
  
• Mary Kay Ladone,
  
• Glenn S Boehnlein,
  
• Kevin P. Smith,
  EVP, Bus Dev, GC & Sec